

Listing Pre-Revenue Biotech Companies in Hong Kong - What You Need to Know

July 17, 2020 | Client Update

Since April 2018, the Hong Kong Stock Exchange has had a regime for listing biotech companies that have yet to record any revenue, which is an important first step towards opening up the Hong Kong market to companies at the pre-revenue stage that are of good quality but are not yet able to comply with the traditional profit record or large capitalisation and revenue record listing criteria. In the two years following the launch of this regime, 16 pre-revenue biotech companies were listed, raising a total of HK\$39.7 billion.

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

Li He

+852 2533 3306
li.he@davispolk.com

James C. Lin

+852 2533 3368
james.lin@davispolk.com

Miranda So

+852 2533 3373
miranda.so@davispolk.com

This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.

Related materials

[listing_pre_revenue_biotech_companies_in_hong_kong.pdf](#)